215 related articles for article (PubMed ID: 30179056)
21. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
[TBL] [Abstract][Full Text] [Related]
22. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
[TBL] [Abstract][Full Text] [Related]
23. Predictors of late bowel toxicity using three different methods of contouring in patients undergoing post-operative radiation for cervical cancer.
Chopra S; Krishnatry R; Dora T; Kannan S; Thomas B; Sonawone S; Engineer R; Paul S; Phurailatpam R; Mahantshetty U; Shrivastava S
Br J Radiol; 2015; 88(1055):20150054. PubMed ID: 26394195
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
25. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
26. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
27. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
Corbeau A; Kuipers SC; de Boer SM; Horeweg N; Hoogeman MS; Godart J; Nout RA
Radiother Oncol; 2021 Nov; 164():128-137. PubMed ID: 34560187
[TBL] [Abstract][Full Text] [Related]
28. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study.
Rattan R; Kapoor R; Bahl A; Gupta R; Oinam AS; Kaur S
Ann Transl Med; 2016 Feb; 4(4):70. PubMed ID: 27004217
[TBL] [Abstract][Full Text] [Related]
29. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
30. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
31. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
[TBL] [Abstract][Full Text] [Related]
32. A dosimetric analysis of tomotherapy based intensity modulated radiation therapy with and without bone marrow sparing in gynecologic malignancies.
Platta CS; Bayliss A; McHaffie D; Tome WA; Straub MR; Bradley KA
Technol Cancer Res Treat; 2013 Feb; 12(1):19-29. PubMed ID: 22974331
[TBL] [Abstract][Full Text] [Related]
33. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation.
Kumar T; Schernberg A; Busato F; Laurans M; Fumagalli I; Dumas I; Deutsch E; Haie-Meder C; Chargari C
Cancer Manag Res; 2019; 11():6285-6297. PubMed ID: 31372035
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].
Du XX; Yang H; Zhang HJ; Li LA; Fan WS; Meng YG
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):679-686. PubMed ID: 29060966
[No Abstract] [Full Text] [Related]
35. Initial Report of Pencil Beam Scanning Proton Therapy for Posthysterectomy Patients With Gynecologic Cancer.
Lin LL; Kirk M; Scholey J; Taku N; Kiely JB; White B; Both S
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):181-189. PubMed ID: 26372435
[TBL] [Abstract][Full Text] [Related]
36. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
[TBL] [Abstract][Full Text] [Related]
37. Effect of Pelvic Bone Marrow Sparing Intensity Modulated Radiation Therapy on Acute Hematologic Toxicity in Rectal Cancer Patients Undergoing Chemo-Radiotherapy.
Huang W; Dang J; Li Y; Cui HX; Lu WL; Jiang QF
Front Oncol; 2021; 11():646211. PubMed ID: 33968746
[TBL] [Abstract][Full Text] [Related]
38. Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer.
Bao Z; Wang D; Chen S; Chen M; Jiang D; Yang C; Liu H; Dai J; Xie C
Radiat Oncol; 2019 Aug; 14(1):118. PubMed ID: 31378200
[TBL] [Abstract][Full Text] [Related]
39. Pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis.
Zhou P; Zhang Y; Luo S; Zhang S
Radiother Oncol; 2021 Dec; 165():103-118. PubMed ID: 34718055
[TBL] [Abstract][Full Text] [Related]
40. The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer.
Yang X; Li Z; Zhang L; Li H; Yang X; Sun Y; Liu L; Fu J
J Cancer; 2023; 14(6):895-902. PubMed ID: 37151393
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
